TABLE 1.

Subject characteristics of Alzheimer’s disease (AD) brain samples

	APOE ε4 non-carrier (N = 158)		APOE ε4 carrier (n = 311)
	Female (n = 79)	Male (n = 79)	Female (n = 166)	Male (n = 145)	Overall (n = 469)
Age at death (years)	82 (57, 98)	78 (55, 93)	83 (55, 100)	81 (57, 95)	82 (55, 100)
Braak stage
IV	9 (11.4%)	14 (17.7%)	22 (13.3%)	26 (17.9%)	71 (15.1%)
V	27 (34.2%)	33 (41.8%)	39 (23.5%)	44 (30.3%)	143 (30.5%)
VI	43 (54.4%)	32 (40.5%)	105 (63.3%)	75 (51.7%)	255 (54.4%)
Thal phase
2	1 (1.3%)	1 (1.3%)	1 (0.6%)	0 (0.0%)	3 (0.6%)
3	6 (7.6%)	11 (14.1%)	8 (4.8%)	7 (4.8%)	32 (6.8%)
4	4 (5.1%)	6 (7.7%)	17 (10.2%)	10 (6.9%)	37 (7.9%)
5	68 (86.1%)	60 (76.9%)	140 (84.3%)	128 (88.3%)	396 (84.6%)
CAA score	0.40 (0, 2.60)	0.50 (0, 2.20)	0.80 (0, 4.00)	0.80 (0, 3.88)	0.80 (0, 4.00)

The sample median (minimum, maximum) is given for continuous variables. Information was unavailable for Thal phase (n = 1).

Abbreviation: APOE, apolipoprotein E; CAA, cerebral amyloid angiopathy